Ernexa Therapeutics Inc.
corporate_fare Company Profile
Ernexa Therapeutics Inc. (NASDAQ:ERNA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for ERNA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-30, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for ERNA spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- Ernexa's ERNA-101 Clears Key Safety Hurdles, IND Filing Set for Q4
- Ernexa's ERNA-201 Shows Disease-Modifying Activity in Arthritis Model, Paving Way for ERNA-101 IND
- Ernexa Q2 2026: Cash Drops to $5M, Going Concern Relies on ATM Sales; Nasdaq Compliance Regained but Under Monitor
- Independent Study Shows ERNA-101 Combo Clears Tumors in 67% of Ovarian Cancer Models
- Ernexa Therapeutics Reaffirms IND/FIH Timelines, Details Strong Preclinical Data, and Confirms Sufficient Capital
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 14,361 shares in ERNA as of the September 15, 2026 settlement, a 27.5% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 38.1% of ERNA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ERNA, detected from its recent SEC filings · based on capital-structure filings through 2026-05-11.
Highly Dilutive Equity Incentive Plan Proposed · Annual Meeting Set for July 1, 2026
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →